Third Rock Ventures V has completed the sale of $5.38 million worth of stock in Rapport Therapeutics. This transaction reflects the venture firm's ongoing strategy to manage its investment portfolio within the biotechnology sector. The sale is part of Third Rock's broader efforts to capitalize on market opportunities and optimize returns for its investors. Further details regarding the implications of this sale for both Third Rock Ventures and Rapport Therapeutics have not been disclosed.
Related Articles
Don't miss out on breaking stories and in-depth articles.